TRI-AAT9-1

HANGZHOU, China I September 30, 2024 I Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR) has completed the dosing of the first patient in the Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG). The Phase 2 study is a randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of three dose levels of DR10624 in adult SHTG patients, who have mean fasting triglycerides of greater than or equal to 5.65 mmol/L (500 mg/dL) at screening. A total of 72 participants will be enrolled in the study. “DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GLP-1R, and glucagon receptor (GCGR). Developed using Doer Bio’s proprietary MultipleBody® platform technology, DR10624 was engineered to exhibit balanced activity for metabolic diseases. In non-clinical studies, DR10624 has demonstrated extraordinary potency in reducing body weight, lowering triglycerides, normalizing blood lipids, and improving liver function.” said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio. “We’re excited to announce the dosing of first patient in our Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia. Patients with SHTG, particularly those with uncontrolled hypertriglyceridemia, face a heightened risk of developing acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). This Phase 2 study is designed to identify the optimal dose for pivotal Phase 3 clinical trials. We are eager to advance DR10624 as a potential treatment for patients struggling with SHTG”. commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio. More information about the Phase 2 clinical trial is available at clinicaltrials.gov (NCT06555640) About Doer Bio Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”) is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers. Doer Bio has developed multiple proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody. For more information about Doer Bio, please visit www.doerbio.com . SOURCE: Zhejiang Doer Biologics Co.

HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR) has completed the dosing of the first patient in the Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG). The Phase 2 study is a randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of three dose levels of DR10624 in adult SHTG patients, who have mean fasting triglycerides of greater than or equal to 5.65 mmol/L (500 mg/dL) at screening. A total of 72 participants will be enrolled in the study. "DR10624 is a first-in-class long-acting tri-agonist targeting FGF21R, GLP-1R, and glucagon receptor (GCGR). Developed using Doer Bio's proprietary MultipleBody® platform technology, DR10624 was engineered to exhibit balanced activity for metabolic diseases. In non-clinical studies, DR10624 has demonstrated extraordinary potency in reducing body weight, lowering triglycerides, normalizing blood lipids, and improving liver function." said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio. "We're excited to announce the dosing of first patient in our Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia. Patients with SHTG, particularly those with uncontrolled hypertriglyceridemia, face a heightened risk of developing acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). This Phase 2 study is designed to identify the optimal dose for pivotal Phase 3 clinical trials. We are eager to advance DR10624 as a potential treatment for patients struggling with SHTG". commented Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio. More information about the Phase 2 clinical trial is available at clinicaltrials.gov (NCT06555640) About Doer Bio Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical stage biopharmaceutical company that focuses on the discovery and development of multi-domain based multi-specific biotherapeutics to address unmet medical need in the field of metabolic diseases and cancers. Doer Bio has developed multiple proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody. For more information about Doer Bio, please visit . SOURCE Zhejiang Doer Biologics Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California. Details of the planned presentations are listed below: Revolution Medicines Oral Presentations: Title:Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex InhibitorPresenter:John Knox, Ph.D.Abstract Number:ND03Session:New Drugs on the Horizon: Part 1Date/Time:1:45 – 2:00 p.m. PT on April 7, 2024 Title: RMC-6236, a RAS(ON) Multi-Selective Tri-Complex InhibitorPresenter:Elena Koltun, Ph.D., Wei Lin, M.D. Session:KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology Date/Time: 1:00 – 1:20 p.m. PT on April 9, 2024 Title:Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLCPresenter:Xing Wei, Ph.D.Abstract Number: 6585 Session: Novel Antitumor Agents 5 Date/Time:2:35 – 2:50 p.m. PT on April 9, 2024 Revolution Medicines Poster Presentations: Title:Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC ModelsPresenter:Lillian Seu, Ph.D. Abstract Number:581/4 Session:Immunotherapy Date/Time:1:30 – 5:00 p.m. PT on April 7, 2024 Title: RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft TumorsPresenter:Zhe Chen, M.B.B.S., Ph.D. Abstract Number:3340/28 Session:Novel Antitumor Agents 3 Date/Time: 1:30 – 5:00 p.m. PT on April 8, 2024 Title:The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant CancersPresenter:Priyanka Bapat, Ph.D. Abstract Number: 4709/2 Session: Other Cellular Mechanisms for Anticancer Drug Action Date/Time:9:00 a.m. – 12:30 p.m. PT on April 9, 2024 Collaborator Poster Presentations: Title:RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical ModelsLead RevMed Co-Author:Harshit Shah, Ph.D.Abstract Number:1924/2Session:Drug Resistance 2: RAS GTPaseDate/Time:9:00 a.m. – 12:30 p.m. PT on April 8, 2024 Title: Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS EffectorsLead RevMed Co-Author:Jingjing Jiang, Ph.D. Abstract Number:1927/5 Session:Drug Resistance 2: RAS GTPase Date/Time: 9:00 a.m. – 12:30 p.m. PT on April 8, 2024 Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/ About Revolution Medicines, Inc.Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).